EpCAM (Epithelial Cell Adhesion Molecule) is a well-established biomarker overexpressed in many carcinomas (colon, breast, ovarian, prostate, and pancreatic cancers). Despite its importance, developing high-affinity, selective aptamers against EpCAM has traditionally been limited by:
Researchers, CROs, and diagnostics companies need faster, more reliable approaches to generate aptamers that bind EpCAM with high affinity for use in biosensors, imaging, targeted delivery, and early cancer diagnostics.